Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation

Gerbase, Margaret; Dubois, D; Rothmeier, Claudia; Spiliopoulos, Anastase; Wunderli, Werner; Nicod, Luc Paul Maurice

doi:10.1378/chest.116.5.1265

Scientific article

English

Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation

ContributorsGerbase, Margaret; Dubois, D; Rothmeier, Claudia

; Spiliopoulos, Anastase; Wunderli, Werner; Nicod, Luc Paul Maurice

Published inChest, vol. 116, no. 5, p. 1265-1272

Publication date1999

Abstract

Cytomegalovirus (CMV) disease is one of the major challenges of lung transplantation that may determine outcome. The benefits of ganciclovir prophylaxis seem indisputable, but no consensus has been reached on the optimal duration of therapy. Results with different protocols suggest that efficacy is related to the duration of treatment.

Keywords

Adolescent
Adult
Antibiotic Prophylaxis/economics/methods
Antibodies, Viral/analysis
Antiviral Agents/administration & dosage/economics/therapeutic use
Bronchoalveolar Lavage Fluid/virology
Child
Cost-Benefit Analysis
Costs and Cost Analysis
Cytomegalovirus/immunology/isolation & purification
Cytomegalovirus Infections/economics/epidemiology/prevention & control/virology
Female
Follow-Up Studies
Ganciclovir/administration & dosage/economics/therapeutic use
Graft Rejection/immunology/prevention & control
Humans
Immunosuppressive Agents/therapeutic use
Incidence
Infusions, Intravenous
Lung Transplantation
Male
Middle Aged
Pneumonia, Viral/economics/epidemiology/prevention & control/virology
Prospective Studies
Survival Rate
Switzerland/epidemiology
Treatment Outcome

Affiliation entities

Citation (ISO format)

GERBASE, Margaret et al. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation. In: Chest, 1999, vol. 116, n° 5, p. 1265–1272. doi: 10.1378/chest.116.5.1265

Article (Published version)

Identifiers

PID : unige:72647
DOI : 10.1378/chest.116.5.1265
PMID : 10559085

Journal ISSN0012-3692

591views

0downloads

Creation13/05/2015 15:32:00

First validation13/05/2015 15:32:00

Update14/03/2023 23:17:50

Status update14/03/2023 23:17:50

Last indexation31/10/2024 00:15:31

Archive ouverte UNIGE

Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation

Technical informations